Ensign Peak Advisors, Inc Cassava Sciences Inc Transaction History
Ensign Peak Advisors, Inc
- $55.3 Billion
- Q4 2024
A detailed history of Ensign Peak Advisors, Inc transactions in Cassava Sciences Inc stock. As of the latest transaction made, Ensign Peak Advisors, Inc holds 36,496 shares of SAVA stock, worth $52,554. This represents 0.0% of its overall portfolio holdings.
Number of Shares
36,496
Previous 16,396
122.59%
Holding current value
$52,554
Previous $482,000
82.16%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding SAVA
# of Institutions
189Shares Held
16.4MCall Options Held
3.49MPut Options Held
8.08M-
Black Rock Inc. New York, NY3.22MShares$4.64 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.51MShares$3.62 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.01MShares$1.45 Million0.0% of portfolio
-
State Street Corp Boston, MA997KShares$1.44 Million0.0% of portfolio
-
Ubs Group Ag931KShares$1.34 Million0.0% of portfolio
About CASSAVA SCIENCES INC
- Ticker SAVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,097,900
- Market Cap $57.7M
- Description
- Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...